Tee Labs Incubatee: LinZight Technology Grand Opening
November 2024, Shanghai — Riding the wave of deep integration between AI and life sciences, Shanghai LinZight Technology Co., Ltd., （LinZight Technology ）incubated by Tee Labs, was officially launched in Zhangjiang Science City, Shanghai. As a medical data application innovator driven by AI, LinZight aims to become a global leader in building intelligent healthcare ecosystems. The company is dedicated to reshaping paradigms for data interaction and value creation, empowering the full lifecycle value of data through AI, advancing intelligent transformation in life science research and clinical practice, and pioneering a patient-centered, precise, and efficient new era of health.
- PART . 01 Bringing Together Elite Talent to Build an Innovative Ecosystem
LinZight’s founding team comprises seasoned experts in AI and data security, clinical specialists (with deep expertise in oncology, autoimmune diseases, CNS disorders, etc.), biologists, and leading bioinformatics talents. Core team members average over 15 years of industry experience, fostering profound insights and highly efficient collaboration. The team has established extensive strategic partnerships with top-tier hospitals, national biobanks, and innovative pharmaceutical companies worldwide. With rich experience in patient data collection, organization, and analysis across therapeutic areas like oncology, autoimmune diseases, and CNS disorders, LinZight delivers cutting-edge data and AI application services to pharmaceutical partners. Additionally, the core team has published nearly 100 high-impact SCI papers in international journals and holds multiple intellectual property rights, including PCT invention patents and data mining software copyrights.
- PART . 02 Addressing Industry Pain Points with a “Multi-Omics + Clinical” Data Infrastructure
Guided by its mission to “empower life with data,” LinZight leverages its proprietary AI platform to build a leading multi-omics and clinical real-world data fusion engine. This core engine bridges the gap between massive genomic data and clinical real-world information in complex disease areas (e.g., oncology, autoimmune diseases, CNS disorders), tackling data silos through deep integration of patient multi-omics data (genomics, transcriptomics, etc.) and full-cycle clinical records (imaging, long-term follow-up, etc.). It provides high-quality data foundations and AI analytics for clinical decision-making, research exploration, and drug discovery.
Pioneering a “data stays put, tools move” model, LinZight enables secure multi-center collaboration while strictly protecting medical data privacy, ensuring safe and efficient data value extraction. With this robust data foundation and innovative approach, LinZight’s business model focuses on empowering pharmaceutical companies in three key areas:Drug Discovery;Clinical Trial Optimization;Biomarker Mining.
- PART . 03 Co-Creating the Future with Technology
Dr. Ni Lin, CEO of LinZight, stated: “We stand at a revolutionary moment where AI is reshaping the value of healthcare data. LinZight’s mission extends beyond unlocking the vast potential of dormant data – we aim to build and empower an open, collaborative ecosystem for accessible medical AI. We eagerly look forward to partnering with global industry leaders to bring precise data insights to every clinical decision and ignite hope for more lives through cutting-edge AI.”
Contact LinZight Technology
Website: https://linzight.com
Business Inquiries: info@linzight.com
Address: Floor 13, Building 2, No. 4560 Jinke Road, Pudong New Area, Shanghai